Pre-congress virtual satellite symposium

Unlocking the potential: IL-23 pathway
in immune-mediated diseases

Wednesday, 18th May, 18:00-19:00 EDT

Simultaneous translation to Spanish and Portuguese will be available


Kilian Eyerich, MD
◉ Chair and professor in the Department of Dermatology and Venereology at the University of Freiburg in Freiburg, Germany
◉ He is principal investigator in numerous translational research projects and clinical trials in the field.
◉ He has published more than 150 scientific articles in peer-reviewed journals such as The New England Journal of Medicine.
Brian G. Feagan, MD, FRCPC
◉ Professor of Medicine in the Departments of Medicine (Division of Gastroenterology), Epidemiology, and Biostatistics at Western University (UWO) in London, Ontario, Canada.
◉ His research efforts focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease
◉ He has authored over 500 articles and book chapters
Dennis McGonagle, FRCPI, PhD
◉ Head of Experimental Rheumatology in the Academic Unit for Musculoskeletal Diseases at the University of Leeds in Leeds, UK
◉ He is well known for his work with psoriatic arthritis (PsA) and has published several key articles relevant to understanding disease mechanisms in PsA
◉ He has published over 450 peer-reviewed articles on these various topics.

Learning Objectives

After attending this event, participants should be able to:
◉ Examine the role of the interleukin (IL)-23 pathway in the pathophysiological mechanisms driving immune-mediated disease progression
◉ Describe the efficacy and safety data on targeting the IL-23 pathway in psoriatic arthritis (PsA), psoriasis (PsO), and inflammatory bowel disease (IBD), and consider how these data impact clinical practice


◉ 18:00  Welcome and introduction, Dennis McGonagle
 18:05 – The IMID universe and IL-23: PsA – PsO – IBD. Kilian Eyerich, Dennis McGonagle, Brian Feagan
 ◉ 18:50  Q&A
 ◉ 19:00  Closing remarks. Kilian Eyerich
*This session is for healthcare professionals only.